Post nirmatrelvir/ritonavir erythema multiforme in a patient with coronavirus disease infection

Erythema multiforme (EM), an immune-mediated skin condition, can occur after infection or following the use of medications. In this study, we describe a patient who developed EM after nirmatrelvir/ritonavir administration. An 81-year-old woman presented with fever and dyspnea. Laboratory investigati...

Descripción completa

Detalles Bibliográficos
Autores principales: Tavares-Júnior, José Wagner Leonel, Pompeu, José Carlos Jucá, Galvão, Luiz Eduardo Garcia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sociedade Brasileira de Medicina Tropical - SBMT 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10238063/
https://www.ncbi.nlm.nih.gov/pubmed/37283342
http://dx.doi.org/10.1590/0037-8682-0008-2023
Descripción
Sumario:Erythema multiforme (EM), an immune-mediated skin condition, can occur after infection or following the use of medications. In this study, we describe a patient who developed EM after nirmatrelvir/ritonavir administration. An 81-year-old woman presented with fever and dyspnea. Laboratory investigations showed positive coronavirus disease (COVID-19) based on polymerase chain reaction assay, and she received a 5-day regimen of nirmatrelvir/ritonavir. We observed development of EM after this treatment and initiated prednisone (1 mg/kg) therapy, which led to rapid improvement. Our study is the first to report EM in a patient with COVID-19, who received nirmatrelvir/ritonavir and showed a favorable response.

Ejemplares similares